Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
ETFs with ARNA as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0.16%||iShares MSCI Indonesia ETF (EIDO)||+0.63 (2.97%)|
Company Description (as filed with the SEC)
We are embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors, or GPCRs, to patients. Our focus is discovering, developing and commercializing drugs to address unmet medical needs, and we have an internally discovered drug, lorcaserin, that is being marketed and a pipeline of novel drug candidates that we intend to advance. Lorcaserin, our first and only approved drug, is approved for marketing in the United States and South Korea for the indication of weight management, and is being commercialized under the brand name BELVIQ® (which is pronounced as "BEL-VEEK"). BELVIQ was made available by prescription in the United States in June 2013 and in South Korea in February 2015, and there are pending applications for the regulatory approval of BELVIQ for marketing in a number of additional territories. ... More ...
Where does ARNA fit in the risk graph?
|Annual EPS Est:||$-0.45|
|Quarterly EPS Est:||-0.1|